Detecting disseminated solid tumor cells in hematopoietic samples: Methodological aspects

Haematologia

Volumn 31, Issue 2, 2001, Pages 97-109

  Mehes G ^a   Ambros, P F ^a   Gadner, H ^a  

^a UNIVERSITY OF PÉCS   (Hungary)

Author keywords

Bone marrow; Disseminated tumor cells; Immunology; PCR

Indexed keywords

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISSEMINATED CANCER; FLUORESCENCE ACTIVATED CELL SORTER; HEMATOPOIETIC CELL; HEMATOPOIETIC SYSTEM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOLOGY; INTERMETHOD COMPARISON; MOLECULAR BIOLOGY; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PROGNOSIS; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TARGET CELL; TREATMENT OUTCOME; TUMOR CELL;

HUMANS; IMMUNOLOGIC TESTS; NEOPLASM CIRCULATING CELLS; NEOPLASMS; POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0035207656     PISSN: 00176559     EISSN: None     Source Type: Journal    
DOI: 10.1163/15685590152492918     Document Type: Article

References (80)

1. Clinical relevance of minimal residual cancer in patients with solid malignancies
2. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study
3. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer
4. Treatments of high risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation
5. New developments in high-dose chemotherapy for breast cancer
6. Strategies to eradicate minimal residual disease in small cell lung cancer: High dose chemotherapy with autologous bone marrow transplantation, matrix metalloproteinase inhibitors and BEC2 plus BCG vaccination
7. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy
8. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
9. Monoclonal antibody therapy with edrecolomab in breast cancer patients: Monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow
10. Detection of metastatic tumor cells in routine bone marrow smears by immuno-alkaline phosphatase labelling with monoclonal antibodies
11. Detection of metastatic neuroblastoma in bone marrow: When is routine marrow histology insensitive?
12. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
13. Monoclonal antibodies for detection of occult carcinoma cells in bone marrow of breast cancer patients
14. Methodological analysis of immunocytochemical screening for disseminated nepithelial tumor cells in bone marrow
15. Bone marrow micrometastases in breast cancer patients
16. Immunocytochemical detection of isolated tumor cells in bone marrow of patients with untreated stage C prostatic cancer
17. Micrometastases of bone marrow in localized prostate cancer: Correlation with established risk factors
18. Tumor angiogenesis and micrometastasis in bone marrow of patients with early gastric cancer
19. Frequency and prognostic significance of isolated tumor cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
20. Isolated tumor cells in the bone marrow predict reduced survival in node-negative non-small-cell lung cancer
21. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
22. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
23. Immunocytological detection of isolated tumour cells in the bone marrow of malignant melanoma patients: A new method for the detection of minimal residual disease
24. Immunocytochemical assessment of bone marrow aspirates for monitoring to chemotherapy in small-cell lung cancer patients
25. Detection of neuroblastoma cells in bone marrow using GD2 specific monoclonal antibodies
26. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma
27. MUC1 expression in hematopoietic tissues
28. Expression of MUC-1 epitopes on normal bone marrow: Implications for the detection of micrometastatic tumor cells
29. Flow cytometric assessment of human MIC2 expression in bone marrow, thymus and peripheral blood
30. Immunocytochemical detection of isolated epithelial cells in bone marrow: Non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase
31. Quantitative analysis of disseminated tumor cells in the bone marrow by automated fluorescence image analysis
32. Recent advances in the polymerase chain reaction
33. The Ewing family of tumours-a subgroup of small round cell tumours defined by specific transcripts
34. Molecular cytogenetics in Ewing tumors: Diagnostic and prognostic information
35. Detection of epithelial cancer cells in peripheral blood by reverse transcriptase polymerase chain reaction
36. Detection of cancer cells in peripheral blood stem cells in women with breast cancer by RT-PCR and cell culture
37. High sensitivity detection of minimal residual breast carcinoma using the polymerase chain reaction and primers for cytokeratin 19
38. Cytokeratin 20 mRNA in peripheral venous blood of colrectal carcinoma patients
39. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy
40. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer
41. Blood based reverse transcriptase polymerase chain reaction assays for prostatic specific antigen: Long term follow-up confirms the potential utility of this assay in identifying patients more likely to have (rising PSA) following radical prostatectomy
42. Early clinical evaluation of reverse transcriptase chain reaction (RT-PCR) for tyrosine hydroxylase
43. Sequential detection of tumor cells in the peripheral blood and bone marrow of patients with stage IV neuroblastoma by the reverse transcription-polymerase chain reaction for tyrosine hydroxylase mRNA
44. Detection of neuroblastoma cells in CD34+selected peripheral stem cell suspensions: A combination of tyrosine hydroxylase nested RT-PCR and anti-ganglioside GD2 immunocytochemistry
45. Polymease chain reaction detection of melanoma cells in the circulation: Relation to clinical stage, surgical treatment and recurrence from melanoma
46. The detection of tyrosinase-specific mRNA in bone marrow is not more sensitive than in blood for the demonstration of micrometastatic melanoma
47. A seminested RT-PCR assay for HER2/neu: Initial validation of a new method for the detection of disseminated breast cancer cells
48. Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction
49. Molecular detection of GAGE expression in peripheral blood and bone marrow: Utility as a tumor marker for neuroblastoma
50. Utilization of polymerase chain reaction technology in the detection of solid tumors
51. Molecular detection of cancer cells in bone marrow and peripheral blood of patients with operable breast cancer. Comparison of CK19, MUC1 and CEA using RT-PCR
52. Limitations of reverse transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow
53. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro
54. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells
55. CK20 gene expression: Technical limits for the detection of circulating tumor cells
56. Analytical variables of reverse transcription-based detection of disseminated prostate cells
57. Detection of micrometastases in colorectal cancer patients by K19 and K20 reverse-transcription polymerase chain reaction
58. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination
59. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases specificity of detection of prostatic cells in the blood
60. Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer
61. Detection and analysis of cancer cells in blood and bone marrow using a rare event imaging system
62. Unequivocal identification of tumor cells in the bone marrow by combining immunological and genetic approaches-functional and prognostic information
63. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS
64. Immunomagnetic separation for enrichment and sensitive detection of disseminated tumour cells in patients with head and neck SCC
65. The use of the CELLection kit in the isolation of carcinoma cells from mononuclear cell suspensions
66. Increased sensitivity for detection of micrometastases in bone marrow/peripheral blood cell products from breast-cancer patients by negative immunomagnetic separation
67. Detection and characterization of carcinoma cells in the blood
68. Detection of circulating tumor cells in patients with breast and ovarian cancer by molecular cytogenetics
69. Sensitive fluorescent in situ hybridization method for the characterization of breast cancer cells in bone marrow aspirates
70. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease
71. Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunogloulin and T-cell receptor loci by LightCycler technology
72. Simultaneous detection and quantification of minimal residual disease in childhood acute lymphoblastic leukemia using real-time polymerase chain reaction
73. A method for quantification of absolute amounts of nucleic acids by RT-PCR and a new mathematical model for data analysis
74. Quantitative RT-PCR pitfalls and potential
75. Comparison of immunocytochemistry, reverse transcriptase polymerase chain reaction and nucleic acid sequence-based amplification for the detection of circulating breast cancer cells
76. Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: Comparison of quantitative polymerase chain reaction and immunocytochemical techniques
77. Comparison of molecular cytokeratin 19 reverse tarnscriptase polymerase chain reaction (CK19 RT.PCR) and immunocytochemical detection of breast cancer cells in hematopoietic harvests
78. International Union Against Cancer: Classification of isolated tumor cells and micrometastasis
79. Standardization of the immunocytochemical detection of cancer cells in BM and blood: Establishment of objective criteria for the evaluation of immunostained cells
80. Re: Classification of isolated tumor cells and micrometastasis